Last €65.46 EUR
Change Today -0.299 / -0.45%
Volume 5.6K
As of 7:33 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-reg (NOT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/4/14 - €67.23
52 Week Low
07/31/13 - €53.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVARTIS AG-REG (NOT)

novartis ag-reg (NOT) Details

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. The company’s Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company’s Vaccines and Diagnostics division provides preventive human vaccines. Its Consumer Health division offers over-the-counter medicines comprising readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. The company distributes its OTC products through various channels, such as food, drug, and mass retail outlets, as well as pharmacies; and Animal Health products directly and through wholesalers of veterinary products. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

135,000 Employees
Last Reported Date: 04/24/14
Founded in 1895

novartis ag-reg (NOT) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.3.1M
Chief Financial Officer
Total Annual Compensation: SFr.747.1K
President of Institutes for Biomedical Resear...
Total Annual Compensation: $1.9M
Division Head of Novartis Pharmaceuticals and...
Total Annual Compensation: $2.0M
Division Head of Animal Health and Member of ...
Total Annual Compensation: SFr.1.4M
Compensation as of Fiscal Year 2013.

novartis ag-reg (NOT) Key Developments

Novartis AG's Leukemia Treatment CTL019 Gets FDA Breakthrough Therapy Status

Novartis AG announced that the United States Food and Drug Administration has granted breakthrough therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia. The breakthrough therapy filing was submitted by the University of Pennsylvania's Perelman School of Medicine which has an exclusive global agreement with Novartis to research, develop and commercialize personalized CAR T cell therapies for the treatment of cancers. The FDA Breakthrough Therapy designation is intended to expedite the development and review of new medicines that treat serious or life-threatening conditions if the therapy has demonstrated substantial improvement over an available therapy on at least one clinically significant endpoint.

Sandoz Launches Hypertension and Hypercalcemia Drugs in Japan

Sandoz, the generic pharmaceutical division of Novartis, has launched Valsartan, Losarhyd and zoledronic acid, in Japan. Valsartan and Losarhyd are indicated for the treatment of hypertension and Zoledronic Acid for hypercalcemia of malignancy. Valsartan is a generic version of Novartis' Diovan Tablets, zoledronic acid is a generic version of Novartis' Zometa for i.v. infusion 4mg/5mL and Losarhyd is a generic version of MSD's Preminent Tablets LD.

Sandoz Commercialises Generic Version of Avelox in Spain

Sandoz, the generics division of Novartis has begun the marketing in Spain of the antibiotic "Sandoz moxifloxacin tablets 400 mg". The new antibiotic marketed by Sandoz is the bioequivalent of Avalox/Avelox produced by Bayer (Germany), whose patent protection has expired. The European Medicines Agency has approved Avalox/Avelox for the treatment of bacterial infections: acute exacerbation of chronic bronchitis; community-acquired pneumonia, except severe cases; and acute bacterial sinusitis (adequately diagnosed). The Sandoz generic version of the product in the Spanish pharmaceutical market will be available for the same indications and will provide more patient access to the antibiotic with a more affordable price.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOT:GR €65.46 EUR -0.299

NOT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merck & Co Inc $58.58 USD +0.03
Nestle SA SFr.68.40 CHF -0.05
Pfizer Inc $30.00 USD -0.05
Roche Holding AG SFr.262.40 CHF +0.20
Procter & Gamble Co/The $81.61 USD -0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation NOT Industry Range
Price/Earnings 22.9x
Price/Sales 3.7x
Price/Book 3.1x
Price/Cash Flow 25.0x
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at